Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Leases (2022 - 2025)

Oramed Pharmaceuticals' Operating Leases history spans 4 years, with the latest figure at $540000.0 for Q4 2025.

  • For Q4 2025, Operating Leases changed N/A year-over-year to $540000.0; the TTM value through Dec 2025 reached $540000.0, changed N/A, while the annual FY2025 figure was $540000.0, N/A changed from the prior year.
  • Operating Leases reached $540000.0 in Q4 2025 per ORMP's latest filing, down from $589000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.1 million in Q1 2022 to a low of $120000.0 in Q1 2025.
  • Average Operating Leases over 4 years is $535000.0, with a median of $540000.0 recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 61.74% in 2023, then skyrocketed 216.67% in 2025.
  • A 4-year view of Operating Leases shows it stood at $894000.0 in 2022, then crashed by 61.74% to $342000.0 in 2023, then plummeted by 45.61% to $186000.0 in 2024, then soared by 190.32% to $540000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Operating Leases are $540000.0 (Q4 2025), $589000.0 (Q3 2025), and $648000.0 (Q2 2025).